SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.Â
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
â–¸ Case Studies â–¸ Page 2
Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.
Learn how Syngene supported a pharma company in developing and manufacturing lab-scale and later Tox batches of its target molecule through an improved synthesis route. All this while meeting chemical purity requirements of >98%.
Learn how Syngene’s novel approach helped synthesize a complex 11-mer cyclic peptide for use in drug therapies.
Learn how Syngene partnered with a biotech company to deliver pre-IND to IND Safety studies in just three months for a treatment therapy for gut-brain diseases.
Learn how Cytopeutics partnered with Syngene to conduct safety and tumorigenicity studies for its hMSC product in appropriate animal models as per regulatory guidelines.
Learn how Syngene developed an antiparasitic tablet for dogs containing multiple APIs (one of which is a very low dose) in just six months.
Learn how Syngene partnered with a U.S.-based biotech company to develop and manufacture a first-in-class treatment for a rare disease affecting children.
Learn how Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101, while ensuring high chiral purity of 98% during GMP manufacturing
How Syngene achieved cost minimization and quick turn-around time when scaling a client’s drug compound from lab-scale to cGMP-scale using the ‘SELECT’ criteria.
Learn how a partnership with a leading global biopharma for outsourced Bioanalytical studies for Large Molecule therapeutics evolved into a co-development partnership nearing a decade.
Learn why Baxter chose to partner with Syngene for Stability studies, the business flow, governance mechanism and metrics that were implemented, which enabled a mutully successful collaboration.
© 2024. Syngene International Limited
We use cookies to improve your experience on our site and show you information relevant to your requirements.
To find out more, read our Privacy Policy and Cookies Policy.